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The efficacy and toxicity of
radiation therapy for local-
ized prostate cancer in
CHHiP (Conventional or
Hypofractionated High Dose
Intensity Modulated Radio-
therapy in Prostate Cancer)
trial participants
aged  75 years was
compared with patients
aged < 75 years. There was
no evidence of a difference
in biochemical or clinical
recurrenceefree survival or
clinically significant toxicity
between the older and
younger patient groups.
Hypofractionated radiation
therapy is an effective and
well-tolerated treatment for
localized prostate cancer in
an elderly population with
good performance status.Purpose: Outcome data on radiation therapy for prostate cancer in an elderly popula-
tion are sparse. The CHHiP (Conventional or Hypofractionated High Dose Intensity
Modulated Radiotherapy in Prostate Cancer) trial provides a large, prospectively
collected, contemporary dataset in which to explore outcomes by age.
Methods and Materials: CHHiP participants received 3 to 6 months of androgen
deprivation therapy and were randomly assigned (1:1:1) to receive 74 Gy in 37 frac-
tions (conventional fractionation), 60 Gy in 20 fractions, or 57 Gy in 19 fractions.
Toxicity was assessed using clinician-reported outcome (CRO) and patient-reported
outcome questionnaires. Participants were categorized as aged < 75 years or 
75 years. Outcomes were compared by age group.
Results: Of 3216 patients, 491 (15%) were aged  75 years. There was no difference
in biochemical or clinical failure rates between the groups aged < 75 years and 
75 years for any of the fractionation schedules. In the group aged  75 years,
biochemical or clinical failureefree rates favored hypofractionation, and at 5 years,
they were 84.7% for 74 Gy, 91% for 60 Gy, and 87.7% for 57 Gy. The incidence
of CRO (grade 3) acute bowel toxicity was 2% in both age groups. The incidence
of grade 3 acute bladder toxicity was 8% in patients aged < 75 years and 7% in those
aged  75 years. The 5-year cumulative incidence of CRO grade  2 late bowel side
effects was similar in both age groups. However, in the group aged  75 years, there
was a suggestion of a higher cumulative incidence of bowel bother (small or greater)
with 60 Gy compared with 74 Gy and 57 Gy. Patient-reported bladder bother was
slightly higher in the group aged  75 years than the group aged < 75 years, and there
was a suggestion of a lower cumulative incidence of bladder bother with 57 Gy
compared with 74 Gy and 60 Gy in patients aged  75 years, which was not evident
in those aged < 75 years.
Conclusions: Hypofractionated radiation therapy appears to be well tolerated and
effective in men aged  75 years. The 57-Gy schedule has potential advantages in that
it may moderate long-term side effects without compromising treatment efficacy in
this group.  2018 Published by Elsevier Inc.Introduction
Prostate cancer (PCa) is the most common cancer in men in
the United Kingdom, with 46,690 new cases and 11,287
deaths in 2014 (1). Fifty-four percent of all new cases of
PCa are diagnosed in men aged > 70 years, with the
highest incidence in men aged > 90 years (1). Management
options for localized disease include active surveillance in
patients with low-risk disease, external beam radiation
therapy, radical prostatectomy, and watchful waiting in
those in whom radical treatment is not suitable.
The Conventional or Hypofractionated High Dose In-
tensity Modulated Radiotherapy in Prostate Cancer
(CHHiP) trial (CRUK/06/016) compared conventional and
hypofractionated high-dose intensity modulated radiation
therapy (HFRT) for PCa (2). The hypofractionated regimen
of 60 Gy in 20 fractions was shown to be noninferior to the
conventional fractionation of 74 Gy in 37 fractions, sup-
porting its use as a new standard of care for external beam
radiation therapy for PCa.Although age is not a factor in the likelihood of a patient
completing radiation therapy (3), elderly patients are
generally underrepresented in clinical trials, resulting in the
lack of a robust evidence base (4, 5). The median age in the
CHHiP trial was 69 years (range, 44-85 years). This reflects
the age-related incidence of PCa and the appropriate use of
a patient’s performance status rather than age to direct
treatment decisions. In this exploratory analysis of the
CHHiP data, we compare treatment outcomes in terms of
time to biochemical or clinical failure (BCF) and treatment-
related toxicity in patients categorized as aged < 75 years
or  75 years.
Methods and Materials
Study design and randomization
The CHHiP study design has been described elsewhere (2).
In brief, male patients aged  16 years with a World Health
Organization performance status of 0 or 1 and
Volume 100  Number 5  2018 Hypofractionated RT for prostate cancer in elderly 1181histologically proven T1bN0M0 to T3aN0M0 PCa were
eligible. Patients with T3 tumors and a Gleason score  8
or with a life expectancy < 10 years were ineligible.
Initially, men with a prostate-specific antigen (PSA)
level  40 ng/mL and a risk of pelvic lymph node
involvement < 30% were eligible, but this was revised in
August 2006 to a requirement of PSA level < 30 ng/mL
and a risk of seminal vesicle involvement < 30% to reflect
the developing consensus of a need for long-term androgen
deprivation therapy (ADT) in men with locally advanced
disease. The trial was reviewed by the London Multicentre
Research Ethics Committee (04/MRE02/10) and was in
accordance with the Code of Ethics of the World Medical
Association (Declaration of Helsinki).
Men were randomized (1:1:1) to receive 74 Gy in 37
fractions over a period of 7.4 weeks (conventional frac-
tionation) or 1 of 2 hypofractionated regimens using daily
fractions of 3 Gy: 60 Gy in 20 fractions over a period of
4 weeks or 57 Gy in 19 fractions over a period of
3.8 weeks. Randomization was stratified for National
Comprehensive Cancer Network (NCCN) risk classification
and treatment center but not patient age. It was not possible
to mask patients or clinicians to treatment allocation.
Procedures
Three to six months of ADT before and during radiation
therapy was mandated in men with NCCN intermediate-
and high-risk disease but was optional in those with low-
risk disease. All radiation therapy was given using an
intensity modulated radiation therapy technique. Further
details of the treatment and its quality assurance have
been reported previously (2). PSA concentrations were
recorded before commencing ADT and radiation therapy
and then at weeks 10, 18, and 26 after radiation therapy,
after which they were recorded at 6-month intervals for
5 years and then annually.
Acute and late toxicity was assessed using clinician-
reported outcome (CRO) grading systems and patient-
reported outcome (PRO) questionnaires. The Radiation
Therapy Oncology Group (RTOG) system (6) was used
to score toxicity every week during radiation therapy and
at weeks 10, 12, and 18. Bowel, bladder, and sexual
function assessments were made before ADT and the
start of radiation therapy and were graded according to
the Late Effects on Normal Tissues: Subjective/Objec-
tive/Management (LENT/SOM) (7) and Royal Marsden
Hospital (RMH) (8) scoring systems. Late toxicity was
collected every 6 months for 2 years and annually
thereafter until 5 years using all 3 toxicity scales. Men
participating in a PRO substudy received questionnaires
at baseline if they had not yet started ADT, and all men
received questionnaires before radiation therapy and at
10 weeks and 6, 12, 18, and 24 months after the start of
radiation therapy and then annually until 5 years was
reached. Further details of the PRO substudy are pre-
sented elsewhere (9).Outcomes
BCF was the primary endpoint. The Phoenix Consensus
guideline of a PSA concentration greater than the nadir plus
2 ng/mL (10) was used after 2007 and applied retros-
pectively to patients recruited before this date. Other recur-
rence (failure) events included recommencement of ADT,
local recurrence, lymph node or pelvic recurrence, and
distant metastases. Acute toxicity was reported as the highest
grade of bowel and bladder toxicity in the first 18 weeks
from the start of radiation therapy. CRO late toxicity out-
comes were reported using the time to first grade 2 or greater
toxic effect using the RTOG, LENT/SOM, and RMH scoring
systems. PROs of interest were time to first small or greater
overall bowel bother and overall urinary bother reported as
single items on the University of California, Los Angeles
Prostate Cancer Index (UCLA-PCI) (11) and 50-item
Expanded Prostate Index Composite (EPIC-50) (12)
questionnaires.
Statistical considerations
All analyses presented are exploratory post hoc subgroup
analyses. As this was a nonrandomized comparison, statistical
comparisons were made for the baseline demographic data
presented by age group (<75 years and 75 years) (t test,
Mann-Whitney test, c2 test, and c2 trend test were used as
appropriate). Kaplan-Meier methods were used to analyze
time-to-event data. Comparisons of each hypofractionated
regimen with the 74-Gy regimen were made within each age
group using the log-rank test. Hazard ratios (HRs) < 1
favored hypofractionated radiation therapy. Acute and late
toxicity data were analyzed using the same methods as pre-
viously described (2), with treatment comparisons made
within each age group separately. Toxicity of grade 2 at
5 years from starting radiation therapy was of primary inter-
est. PROs were analyzed using the same methods as previ-
ously described (9); small or greater bother was of primary
interest. A significance level of 1% was used because of
multiple testing. All analyses were conducted using Stata
software (version 13.0; StataCorp) and were based on the
primary analysis data snapshot taken on September 8, 2015.
Results
Baseline demographic data
The baseline demographic data of patients in the group
aged < 75 years (nZ 2725) and the group aged  75 years
(n Z 491) are shown in Table 1, and medical history in-
formation is shown in Table E1 (available online at www.
redjournal.org). There was a significant difference
(P < .0001) in NCCN risk group distribution between age
groups, with a higher proportion of intermediate-risk dis-
ease than low-risk disease in the group aged  75 years.
The group aged  75 years had more cancers with a
Table 1 Baseline demographic data of patients aged < 75 years and  75 years
Age < 75 y (n Z 2725) Age  75 y (n Z 491) P value
Age, median (IQR), y 67 (63-71) 76 (75-78) <.0001
Treatment group, n (%) .709
74 Gy 898 (33) 167 (34)
60 Gy 925 (34) 149 (30)
57 Gy 902 (33) 175 (36)
NCCN risk group, n (%) <.0001
High risk 321 (12) 64 (13)
Intermediate risk 1956 (72) 391 (80)
Low risk 448 (16) 36 (7)
Intended hormone therapy, n (%) .014
LHRH-positive short-term AA 2264 (84) 436 (89)
150 mg of bicalutamide 357 (13) 46 (9)
MAB 3 (<1) 2 (<1)
Bicalutamidedother 2 (<1) 0 (0)
LHRH alone 0 (0) 2 (<1)
None 86 (3) 4 (<1)
Gleason score, n (%) .018
6 975 (36) 147 (29)
7 1668 (61) 327 (67)
8 82 (3) 17 (4)
Clinical T category, n (%) <.0001
T1 1034 (38) 136 (28)
T2 1452 (53) 314 (64)
T3 236 (9) 41 (8)
TX 1 (<1) 0 (0)
Missing or not done 1 (<1) 0 (0)
Prehormone PSA level
No. with data 2724 490
Median (IQR), ng/mL 9.8 (7.0-14.2) 11.4 (8.6-14.8) <.0001
Prehormone testosterone level
No. with data 1114 146
Median (IQR), nmol/L 12.6 (9.5-16.2) 12.3 (9.5-16.4) .883
Prehormone LH level
No. with data 1033 123
Median (IQR), IU/L 4 (3-6); range, 1-56 5 (3-7); range, 1-30 .024
IGRT used, n (%)
Yes 825 (33) 148 (33) .963
No 1686 (67) 304 (67)
Prostate volume
No. with data 936 217
Median (IQR), cm3 37.0 (28.0-50.0) 42.7 (30.3-54.8) .001
Maximum length of core involvement
No. with data 1451 289
Median (IQR), % 35 (15-60) 40 (20-70) .007
Maximum length of core involvement
No. with data 452 92
Median (IQR), mm 9 (4-17) 12 (7-20) .007
Abbreviations: AA Z Anti-androgen; IGRT Z Image Guided Radiation Therapy; LH Z Luteinising hormone; LHRH Z Luteinising hormone
releasing hormone; MAB Z Maximal Androgen Blockade; NCCN Z National Comprehensive Cancer Network; PSA Z prostate-specific antigen.
Wilson et al. International Journal of Radiation Oncology  Biology  Physics1182Gleason score of 7 but fewer cancers with a Gleason score
of 6 than the group aged < 75 years, and the group aged 
75 years had a larger maximum length of biopsy core
involvement. Median PSA levels were higher in the group
aged  75 years (11.4 ng/mL) than in the group
aged < 75 years (9.8 ng/mL, P < .0001), but prehormonetestosterone levels were similar. Prostate volume was larger
in the group aged  75 years (median, 42.7 cm3) than in the
group aged < 75 years (median, 37.0 cm3; P Z .001).
More patients in the group aged  75 years than in the
group aged < 75 years underwent a previous transurethral
resection of the prostate (13% vs 7%, P < .0001; Table E1,
Volume 100  Number 5  2018 Hypofractionated RT for prostate cancer in elderly 1183available online at www.redjournal.org). Image guided ra-
diation therapy use was similar in the 2 groups, but more
men in the group aged < 75 years received bicalutamide
alone (P Z .014).Time to BCF
Therewas no evidence of a difference inBCFbetween the 2 age
groups (PZ .909) (Fig. 1A). In the group aged< 75 years, the
5-year BCF-free rates were 88.9% (95% confidence interval
[CI], 86.5%-90.9%), 90.5% (95% CI, 88.3%-92.3%), and
85.5% (95% CI, 82.8%-87.8%) in the 74-, 60-, and 57-Gy
groups, respectively (Fig. 1 B). In the group aged  75 years,
the 5-yearBCF-free rateswere 84.7% (95%CI, 77.3%-89.9%),
91.0% (95% CI, 83.7%-95.1%), and 87.7% (95% CI, 80.2%-
92.4%) in the 74-, 60-, and 57-Gy groups, respectively (Fig. 1
C). The BCF-free rates for the 74-Gy group were slightly bet-
ter in the group aged < 75 years than in the group aged 
75 years (in keeping with less favorable presenting features in
the group aged  75 years), which seemed to be favorably
modified by hypofractionation (Fig. 1 C).Acute toxicity
The prevalence of clinician-assessed bowel (Fig. 2 A) and
bladder (Fig. 2 B) toxicity from week 1 to week 18 was
similar in the 2 age groups. There was no evidence of a
difference in peak acute RTOG bowel toxicity (Fig. 2 A)
between age groups (P Z .561), with 34 of 1859 patients
(2%) in the group aged < 75 years and 5 of 289 patients
(2%) in the group aged  75 years experiencing grade 3
bowel toxicity, with no reported grade 4 bowel toxicity.
Within the group aged < 75 years, there was a significant
difference in peak acute bowel toxicity between the control
group and both hypofractionated groups (P < .0001 for
both the 60- and 57-Gy comparisons); however, this did not
reach statistical significance in the group aged  75 years
(P Z .097 for 60 Gy and P Z .054 for 57 Gy) (Table E2,
available online at www.redjournal.org). At 18 weeks, there
was no significant difference in the distribution of the grade
of acute bowel toxicity between age groups (P Z .274).0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
491 461(3) 449(5) 416(13) 348(10) 179(16) 80(6) 43(2)75+
2725 2662(10) 2557(64) 2419(84) 2061(73) 1341(53) 746(24) 451(24)<75
Number at risk (events)
0 1 2 3 4 5 6 7
Years from randomisation
<75 75+
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
902 881(4) 846(28) 796(32) (27)57Gy
925 904(3) 876(14) 838(22) (25)60Gy
898 877(3) 835(22) 785(30) (21)74Gy
Number at risk (events)
0 1 2 3
Years from rand
74Gy 6
HR60: 0.90 (0.69-1.18); P 
HR57: 1.34 (1.04 -1.71 ); P 
A B
Fig. 1. Time to biochemical failure or prostate cancer recurren
aged < 75 years by treatment group (B), and patients aged  7There was no evidence of a difference in peak acute
RTOG bladder toxicity (Fig. 2 B) between age groups
(P Z .920). Grade 3 toxicity and grade 4 toxicity were
recorded in 147 of 1859 patients (8%) and 21 of 1859 (1%),
respectively, in the group aged < 75 years and in 20 of 289
(7%) and 2 of 289 (1%), respectively, in the group
aged  75 years. Within the group aged < 75 years, there
was no significant difference in acute bladder toxicity noted
between the control group and either hypofractionated group
(P Z .969 for 60 Gy and P Z .569 for 57 Gy). However,
within the group aged  75 years, there was more acute
bladder toxicity in the control group than in the 60-Gy group
(P Z .004) but not the 57-Gy group (P Z .083) (Table E2,
available online at www.redjournal.org). The differences had
disappeared by 18 weeks.Late toxicity
There was no evidence of a difference in time to first grade
 2 bowel toxicity using any CRO scale for either hypo-
fractionated group compared with the control group in either
age group (Fig. 3). The 5-year cumulative incidences of
grade  2 RTOG, RMH, and LENT-SOM late bowel side
effects were similar, with rates of 9.9% (95% CI, 8.8%-
11.2%) versus 12.5% (95% CI, 9.5%-16.3%), 13.5% (95%
CI, 12.2%-14.9%) versus 12.9% (95% CI, 10.0%-16.6%),
and 20.4% (95% CI, 18.8%-22.1%) versus 20.4% (95% CI,
16.8%-24.7%), respectively, for the group aged < 75 years
versus the group aged  75 years (Fig. 3). The prevalence of
CRO late side effects was stable over time from 1 to 5 years,
with 2-year grade  2 RTOG, RMH, and LENT-SOM bowel
toxicity in 68 of 2430 patients (3%), 87 of 2413 (4%), and
131 of 2352 (6%), respectively, in the group aged< 75 years
compared with 12 of 413 (3%), 21 of 412 (5%), and 29 of
401 (7%), respectively, in the group aged  75 years for the
74-, 60-, and 57-Gy schedules (Figs. E1-E3, available online
at www.redjournal.org). Patient-reported small or greater
bowel bother peaked at 10 weeks after the start of radiation
therapy and was similar in both age groups (Figs. E4 and E5,
available online at www.redjournal.org). At 2 years, the
prevalence of small or greater bowel bother was 146 of 1159
patients (13%) in the group aged < 75 years and 28 of 1530%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
175 163(1) 158(2) 148(3) 129(4) 59(6) 25(1) 15(0)57Gy
149 138(1) 135(1) 127(1) 105(3) 63(4) 27(1) 14(1)60Gy
167 160(1) 156(2) 141(9) 114(3) 57(6) 28(4) 14(1)74Gy
Number at risk (events)
0 1 2 3 4 5 6 7
Years from randomisation
74Gy 60Gy 57Gy
669 433(25) 237(8) 136(13)
711 470(14) 253(9) 162(9)
681 438(14) 256(7) 153(2)
4 5 6 7
omisation
0Gy 57Gy
= .463
= .022
HR60: 0.54 (0.28-1.05); P = .064
HR57: 0.64 (0.35 -1.18 ); P = .149
C
ce for patients aged < 75 years and  75 years (A), patients
5 years by treatment group (C).
Fig. 2. Prevalence of clinician-assessed Radiation Ther-
apy Oncology Group bowel (A) and bladder (B) toxicity
during week 1 to week 18 from start of radiation therapy for
patients aged < 75 years and  75 years by toxicity grade.
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higher in the group aged  75 years at all time points to
5 years (Figs. E4 and E5, available online at www.
redjournal.org), when the cumulative incidences of small
or greater bowel bother were 32% (95% CI, 30%-35%) and
38% (95% CI, 32%-44%) in the groups aged < 75 years and
 75 years, respectively. Although there was no evidence of
a difference between the fractionation schedules in the group
aged < 75 years, in the group aged  75 years, there was a
suggestion of a higher cumulative incidence of small or
greater bowel bother with 60 Gy compared with 74 Gy (HR,
1.44; 95% CI, 0.90-2.32; P Z .115) or 57 Gy (HR, 0.81;
95% CI, 0.48-1.38; P Z .460), but this did not reach the
conventional level of statistical significance (Fig. 4 A).
There was no certain evidence of a difference in time to
first grade  2 bladder toxicity using CROs for either
hypofractionated group compared with the control group in
either age group (Fig. 5). However, there was a suggestion
of increased RTOG toxicity with 60 Gy in the group aged
< 75 years (P Z .012). The 5-year cumulative incidences
of grade  2 RTOG, RMH, and LENT-SOM late bladderside effects were similar, with rates of 6.6% (95% CI,
5.7%-7.7%) versus 9.2% (95% CI, 6.9%-12.3%), 25.9%
(95% CI, 24.2%-27.7%) versus 32.1% (95% CI, 27.6%-
37.0%), and 38.1% (95% CI, 36.1%-40.1%) versus 40.5%
(95% CI, 35.7%-45.7%), respectively, for the group
aged < 75 years versus the group aged  75 years (Fig. 5).
The 2-year prevalence of grade  2 RTOG, RMH, and
LENT-SOM bladder toxicity was 32 of 2430 patients (1%),
193 of 2417 (8%), and 287 of 2346 (12%), respectively, in
the group aged < 75 years compared with 8 of 413 (2%), 39
of 410 (10%), and 54 of 399 (14%), respectively, in the
group aged  75 years and was stable over time (Figs. E6-
E8, available online at www.redjournal.org). Grade 1 RMH
bladder symptoms were persistently greater in the group
aged  75 years both before and after treatment (Fig. E7 A,
available online at www.redjournal.org). Patient-reported
small or greater bladder bother peaked at 10 weeks after
the start of radiation therapy and was similar in both age
groups (Figs. E9 and E10, available online at www.
redjournal.org). At 2 years, the prevalence of small or
greater bladder bother was 140 of 1154 patients (12%)
and 33 of 149 (22%) in the groups aged < 75 years and
 75 years, respectively, remaining slightly higher in the
group aged  75 years at all time points to 5 years (Figs. E9
and E10, available online at www.redjournal.org), when the
cumulative incidences of small or greater bladder bother
were 30% (95% CI, 28%-33%) and 39% (95% CI, 33%-
46%) in the groups aged < 75 years and  75 years,
respectively. Although there was no difference between the
fractionation schedules in the group aged < 75 years, there
was a suggestion of a lower cumulative incidence of small
or greater bladder toxicity with 57 Gy compared with
74 Gy (HR, 0.71; 95% CI, 0.43-1.16; P Z .163) or 60 Gy
(HR, 1.01; 95% CI, 0.63-1.62; P Z .953) in the group
aged  75 years (Fig. 4 B).
At 2 years, the incidence of LENT/SOM grade 2 sexual
dysfunction was 1402 of 2189 patients (64%) and 262 of 360
(73%) in the groups aged < 75 years and  75 years,
respectively; at 5 years, the incidencewas 825 of 1255 (66%)
and 109 of 161 (68%), respectively. The increased incidence
of erectile dysfunction in the group aged 75 years predated
hormone and radiation therapy and persisted for the 5 years of
follow-up (Fig. E11, available online at www.redjournal.
org). There was no evidence of a difference in time to
grade  2 erectile dysfunction between the fractionation
schedules in either age group (Fig. E12, available online at
www.redjournal.org).Discussion
The poor recruitment of older adults into clinical trials is
thought to be due to functional reserve decline, increased
comorbid conditions, lack of social support, and increa-
sed concomitant medications in elderly patients (13).
When making decisions about their cancer treatment, older
<75 age group ≥75 age group
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889 848(32) 813(20) 769(6) 633(6) 335(7) 17(3)57Gy
906 865(35) 814(29) 765(14) 635(4) 345(3) 13(2)60Gy
878 844(24) 788(34) 742(14) 600(8) 314(11) 12(4)74Gy
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889 841(38) 789(37) 739(16) 598(13) 316(8) 15(2)57Gy
906 864(36) 787(55) 750(7) 619(11) 335(9) 13(2)60Gy
878 837(31) 772(43) 726(17) 586(12) 315(5) 12(4)74Gy
Number at risk (events)
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889 828(54) 762(50) 714(16) 565(14) 290(8) 15(3)57Gy
906 833(67) 732(79) 684(13) 546(17) 287(16) 11(5)60Gy
878 818(47) 724(69) 665(29) 526(17) 281(11) 10(3)74Gy
Number at risk (events)
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168 152(10) 143(5) 135(1) 105(2) 41(2) 0(1)57Gy
143 136(4) 128(7) 117(2) 84(2) 38(1) 1(2)60Gy
162 154(5) 147(4) 131(6) 108(0) 56(1) 3(0)74Gy
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168 154(8) 143(7) 134(2) 106(1) 43(1) 0(2)57Gy
143 135(5) 129(5) 115(4) 84(0) 40(1) 1(1)60Gy
162 155(4) 142(10) 128(3) 105(2) 54(2) 3(0)74Gy
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168 155(7) 140(12) 128(3) 96(2) 40(1) 0(0)57Gy
143 131(9) 116(13) 104(4) 73(0) 33(3) 1(2)60Gy
162 148(11) 130(15) 113(5) 93(3) 51(0) 1(0)74Gy
Number at risk (events)
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HR60 : 0.89 (0.66 -1.19 ); P = .415
HR57 : 0.76 (0.56-1.03); P = .074
HR60 : 1.32 (0.67 -2.60 ); P = .414
HR57 : 1.37 (0.71-2.63 ); P = .368
HR60: 1.04 (0.80 -1.34 ); P = .768
HR57: 1.00 (0.77-1.30 ); P = .993
HR60 : 0.88 (0.46 -1.68 ); P = .657
HR57 : 1.01 (0.55-1.86 ); P = .965
HR60 : 1.09 (0.90 -1.34 ); P = .370
HR57 : 0.79 (0.64-0.99 ); P = .039
HR60 : 1.05 (0.65 -1.71 ); P = .834
HR57 : 0.71 (0.42-1.19 ); P = .165
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Fig. 3. Time to first grade  2 bowel toxicity assessed by Radiation Therapy Oncology Group (A), Royal Marsden Hospital
(B), and Late Effects on Normal Tissues: Subjective/Objective/Management (C) scales for patients aged < 75 years and 
75 years by treatment group.
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discomfort, fear of side effects, and transport issues (14).
In an elderly population, the patient’s functional status and
the presence of “geriatric syndromes” such as dementia,depression, osteoporosis, or falls are associated with
increased chemotherapy toxicity (15). Data on radiation
therapy outcomes and toxicity in an elderly population are
sparse.
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600 501(61) 416(58) 377(18) 328(13) 243(13) 11(14)57Gy
594 476(81) 402(49) 353(13) 290(18) 226(16) 10(10)60Gy
587 482(64) 384(60) 349(13) 295(15) 189(13) 10(6)74Gy
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600 500(61) 412(59) 378(14) 328(14) 249(8) 12(13)57Gy
594 500(56) 425(53) 380(13) 317(18) 242(17) 11(9)60Gy
587 488(56) 397(50) 362(14) 303(21) 203(14) 6(11)74Gy
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93 75(12) 58(9) 53(3) 47(1) 30(0) 0(0)57Gy
88 62(18) 47(13) 42(2) 34(2) 26(2) 1(1)60Gy
90 71(12) 63(6) 57(1) 42(5) 30(3) 1(4)74Gy
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93 78(9) 57(11) 53(2) 46(2) 29(1) 0(2)57Gy
88 65(14) 53(10) 45(3) 36(4) 29(1) 0(2)60Gy
90 74(10) 57(13) 48(5) 36(3) 23(3) 1(2)74Gy
Number at risk (events)
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HR60: 0.95 (0.76 -1.17 ); P = .611
HR57: 0.97 (0.78-1.20); P = .759
HR60: 1.07 (0.87 -1.32); P = .493
HR57: 0.96 (0.78 -1.19); P = .718
HR60: 1.01 (0.63 -1.62 ); P = .953
HR57: 0.71 (0.43-1.16); P = .163
HR60: 1.44 (0.90 -2.32) ; P = .115
HR57: 0.81 (0.48-1.38); P = .460
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Fig. 4. Time to first small or greater bowel (A) and urinary (B) bother for patients aged < 75 years and  75 years by
treatment group.
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there was no evidence of a difference in BCF in the group
aged < 75 years and the group aged  75 years. Results in
the group aged < 75 years mirrored the findings in our pre-
vious report (2), with higher BCF rates in the 57-Gy ran-
domized trial arm. However, in the group aged  75 years,
both 60 Gy and 57 Gy showed higher (91.0% and 87.7%,
respectively) 5-year BCF-free outcomes than 74 Gy (84.7%),
although this was not statistically significant. Equivalent re-
sults were seen in the group aged  75 years and the group
aged < 75 years despite less favorable features at pres-
entation. This imbalance of prognostic factors between age
groups may relate to clinician or patient preference for an
active surveillance strategy with increasing age as observed
previously in a Canadian population-based study (16). We are
not aware of any previous evidence of a relatively beneficial
effect of hypofractionated radiation therapy in older patients
with PCa. This could have resulted from an imbalance of
other unmeasured prognostic factors or perhaps slower or
incomplete testosterone recovery. Alternatively, it may be a
chance finding owing to the relatively small proportion of
elderly patients (15% of the overall trial population).
Although noninferiority of 57 Gy compared with 74 Gy could
not be claimed formally in the whole trial population (5-year
control rate of 85.9% vs 88.3%), the 57-Gy schedule has
potential advantages in that it may moderate long-term sideeffects without a meaningful compromise of treatment effi-
cacy in elderly patients. The 57-Gy schedule has recently
been endorsed by an NHS England guidance for consi-
deration in frail elderly patients (17).
Previously, one study in a mixed cohort of patients
aged > 70 years showed no increase in grade 3 to 4
toxicity in more vulnerable or frail patients (5). To our
knowledge, our study is the first assessment of both CROs
and PROs in elderly patients with PCa treated with HFRT.
While this was not a preplanned analysis and results must
be regarded as exploratory, the large number of patients
recruited to the CHHiP trial permits some observations.
There was no increase in peak acute bowel or bladder
toxicity in the group aged  75 years compared with the
group aged < 75 years, and HFRT appeared well tolerated
in elderly patients. The difference in acute bowel toxicity
between the control and HFRT groups seen in the group
aged < 75 years (P < .0001 for both 60- and 57-Gy
comparisons) failed to reach statistical significance in
the group aged  75 years. This finding is reassuring but
most likely relates to the smaller sample size in the group
aged  75 years. It is important to note that 18 weeks
after radiation therapy, acute bowel toxicity had settled
satisfactorily in both age cohorts, with no differences
between the fractionation schedules. With respect to
acute bladder toxicity, there was a significant increase in
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889 870(9) 836(17) 794(6) 652(2) 344(6) 16(1)57Gy
906 876(24) 830(22) 780(14) 644(11) 351(4) 11(2)60Gy
878 860(8) 820(17) 780(6) 632(6) 335(8) 11(3)74Gy
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889 793(88) 728(51) 672(26) 536(21) 277(20) 14(8)57Gy
906 804(96) 713(71) 655(27) 531(22) 286(17) 9(8)60Gy
878 791(77) 713(61) 660(29) 523(32) 280(8) 8(8)74Gy
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889 751(129) 652(84) 595(29) 459(26) 227(25) 10(9)57Gy
906 748(152) 632(99) 564(35) 434(37) 226(17) 7(12)60Gy
878 740(125) 620(102) 557(37) 427(30) 218(19) 4(13)74Gy
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168 157(5) 147(6) 138(1) 105(3) 42(0) 0(1)57Gy
143 137(3) 133(3) 121(2) 86(1) 39(0) 0(2)60Gy
162 153(6) 146(4) 131(5) 107(2) 52(0) 3(1)74Gy
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168 139(23) 126(9) 115(6) 90(3) 35(4) 0(1)57Gy
143 119(21) 107(11) 96(3) 69(6) 29(4) 0(0)60Gy
162 138(21) 125(11) 110(4) 85(4) 38(5) 2(0)74Gy
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168 140(22) 121(16) 103(10) 79(4) 30(2) 0(3)57Gy
143 113(27) 93(18) 83(3) 56(6) 24(1) 0(2)60Gy
162 139(20) 115(21) 102(5) 77(8) 34(8) 0(2)74Gy
Number at risk (events)
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HR60: 1.58 (1.10 -2.27 ); P = .012
HR57: 0.84 (0.55-1.27); P = .404
HR60 : 0.72 (0.34 -1.53 ); P = .395
HR57 : 0.91 (0.46-1.78); P = .706
HR60: 1.11 (0.92 -1.34 ); P = .264
HR57: 0.99 (0.82-1.19); P = .876
HR60: 1.17 (0.77 -1.76 ); P = .472
HR57: 1.01 (0.67-1.52); P = .966
HR60: 1.06 (0.90 -1.23 ); P = .456
HR57: 0.89 (0.75-1.05); P = .161
HR60 : 1.10 (0.77 -1.58 ); P = .604
HR57 : 0.88 (0.62-1.26); P = .488
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Fig. 5. Time to first grade  2 bladder toxicity assessed by Radiation Therapy Oncology Group (A), Royal Marsden
Hospital (B), and Late Effects on Normal Tissues: Subjective/Objective/Management (C) scales for patients aged < 75 years
and  75 years by treatment group.
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Wilson et al. International Journal of Radiation Oncology  Biology  Physics1188RTOG grade  2 toxicity between the control group and
60-Gy group (P Z .004) but not the 57-Gy cohort
(PZ .083) in the group aged  75 years. This difference
was not seen for the group aged < 75 years (Table E2,
available online at www.redjournal.org). This finding
might reflect a higher incidence of pretreatment bladder
dysfunction and support use of the regimen of 57 Gy in 19
fractions in older men, particularly as this schedule was
not associated with a decrease in treatment efficacy
compared with 74 or 60 Gy.
There were no consistent differences in the prevalence or
cumulative incidence of CRO late bowel toxicity up to
5 years after radiation therapy between the groups aged <
75 years and  75 years. Similar findings were seen using
conventional radiation therapy or HFRT and assessments
with the RTOG, RMH, or LENT-SOM instruments. How-
ever, with the use of PROs, there was a consistent increase
in reporting of bowel bother in the group aged  75 years,
and this appeared to be most pronounced in the 60-Gy
group rather than the 74- or 57-Gy cohort. Fractionation
schedule was not related to bowel bother in the group aged
< 75 years.
There appeared to be more bladder symptoms in the
group aged  75 years compared with the group aged
< 75 years at 5 years measured by the CRO
instruments. This was confirmed using PROs, and all
degrees of bladder bother were increased in the group aged
 75 years. Fractionation schedule appeared unrelated to
bladder bother in the group aged < 75 years, but 57 Gy
appeared to be associated with reduced bother scores in the
group aged  75 years rather than those patients treated
with 74 Gy and 60 Gy, although this failed to reach sta-
tistical significance. Although it is difficult to separate
treatment effects from an increase in urinary symptoms in
an elderly population, this might sound a cautionary note
against dose escalation in more aged patients.
Erectile dysfunction was increased after treatment in the
group aged  75 years. This finding was expected as
increasing age has previously been identified as a risk
factor for erectile dysfunction following ADT and radiation
therapy for PCa (18). Higher levels of dysfunction were
scored using the LENT-SOM instrument compared with
using PROs to assess bother, perhaps reflecting the change
in importance of erectile dysfunction with increasing age.
However, post-ADT testosterone recovery may be delayed
and incomplete in older patients. As having a normal
testosterone level is important in the recovery of erectile
dysfunction, as well as other health issues, it is recom-
mended that this should be assessed after treatment (19).
Conclusions
HFRT using 60 or 57 Gy delivered in 3-Gy fractions ap-
pears to be well tolerated and effective in more elderly men,
and age should not be a barrier to implementing shorterradiation therapy schedules. The 57-Gy schedule has po-
tential advantages in moderating long-term bowel and
bladder side effects while maintaining satisfactory PCa
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